Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by 14czorifertinib Oral Formulation

Research Leaders

6 sponsors active, led by Alpha Biopharma (Jiangsu) Co., Ltd.

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (2)
Phase 2 (1)

Trial Status

Completed2
Recruiting2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (5)

Research Network

Common Treatments

  • 14czorifertinib Oral Formulation1
  • Zorifertinib1
  • Lapatinib In Tandem With Capecitabine1
  • Temozolomide1
  • No Interventions1

Active Sponsors

  • Alpha Biopharma (Jiangsu) Co., Ltd.2
  • Memorial Sloan Kettering Cancer Center1
  • The Methodist Hospital Research Institute1
  • Fudan University1
  • University of Michigan1

Top Investigators

Related Conditions

  • Egfr Mutant Advanced Nonsmall Cell Lung Cancer2
  • Metastatic Breast Cancer1
  • Brain Metastases1
  • Breast Cancer1

Activity Timeline